InsulinSGLT-2iSGLT-2isGLP-1RAGLP-1RAssodium-glucose cotransporter 2 inhibitorssulfonylurea
…d significantly after intervention (−2.0% per quarter; p=0.02). Insulin prescribing rates did not change throughout the study period. T…
25articles mentioning drugs
292drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: GLP-1RA ×
GLP-1RA
This drug is selected. Its supporting articles are shown below.
Articles mentioning GLP-1RA
25 articles · page 2 of 3GLP-1RADPP-4iSGLT-2isodium-glucose cotransporter-2 inhibitorsglucagon-like peptide 1 receptor agoniststype 2 diabetesthyroid cancer
…e estimated the comparative effect of incretin-based therapies (GLP-1RA and dipeptidyl-peptidase-4 inhibitors (DPP-4i)) versus sodium-g…
GLP-1RAexogenous insulinGLAglucagon-like peptide-1 receptor agoniststype 2 diabetes (T2D)T2DClinica ColoniaIR-T2DNCT06655740
…19) remained off exogenous insulin without need for concomitant GLP-1RA, and 84.2% (n=16) maintained a HbA1c ≤7.5%. Oral GLAs were incr…
GLP-1RAGLP-1 receptor agonistsPROSPEROgastroesophageal reflux diseaseGERD
…care, are enterally fed, or are taking GLP-1 receptor agonists (GLP-1RA). Study quality was assessed using the Mixed Methods Appraisal …
DapagliflozinEmpagliflozinGLP-1RASGLT2icanagliflozinsemaglutideMRAmineralocorticoid receptor antagonistsfinerenoneglucagon-like peptide-1 receptor agonists+3 more
…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …
CanagliflozinDapagliflozinfinerenoneEmpagliflozinsemaglutideertugliflozinGLP-1RAMRAMineralocorticoid Receptor AntagonistsCardio-Renal-Metabolic syndrome+3 more
… kidney disease progression by 24% [HR 0.76; 95% CI 0.67–0.87]. Canagliflozin reduced the composite renal outcome [HR 0.66; 95% CI 0.53–0.81]…
SGLT2iSGLT2isGLP-1RAsGLP-1RAtype 2 diabetesatherosclerotic cardiovascular diseasechronic kidney disease
… CI 47.2% to 54.7%) (8.2 million) met indications for either an SGLT2i or a GLP-1RA. Among those with indications for an SGLT2i specif…
GLP-1RADPP-4iGLP-1RAsdipeptidyl peptidase-4 inhibitorshepatocellular carcinomaHCCtype 2 diabetesChinese Clinical Trial RegistryT2DChiCTR2600118495
…analyses were directionally consistent.Conclusion Postoperative GLP-1RA initiation, compared with DPP-4i initiation, was associated wit…
glipizideglyburideglimepiride
… outcome (10%), and incident CKD stages 3–4 (23%) compared with glipizide. However, glyburide was associated with significantly higher ri…
semaglutideliraglutideGLP-1RA-treatedGLP-1RAGLP-1RAstype 2 diabetesnon-arteritic anterior ischaemic optic neuropathy
…ufactured GLP-1RA products (active ingredients: liraglutide and semaglutide) in people with type 2 diabetes and/or overweight/obesity. Pote…
SGLT2iSGLT2isGLP-1RAsGLP-1RAsodium-glucose cotransporter-2 inhibitorsGlucagon-like peptide-1 receptor agoniststype 2 diabetescardiovascular and kidney diseasescardiometabolic diseasesobesity epidemic
…cial in these patients. Remarkably, the benefits of GLP-1RA and SGLT2i are independent of type 2 diabetes status or baseline renal fun…